Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30results about How to "Increasing cell proliferation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Medical devices comprising porous layers for the release of therapeutic agents
InactiveUS20080051881A1Reduce retentionImprove cell adhesionSuture equipmentsStentsMedical deviceBiomedical engineering
In accordance with an aspect of the invention, implantable or insertable medical devices are provided in which a porous layer is disposed over a therapeutic-agent-containing region. In accordance with another aspect of the invention, medical devices are fabricated by a method in which a porous layer is deposited over a therapeutic-agent-containing region using a field-injection-based electrospray technique.
Owner:BOSTON SCI SCIMED INC
Methods For Treating Wounds
InactiveUS20030125264A1Increasing cell proliferationPromote cell growthBiocideCarbohydrate active ingredientsFibroblastPharmaceutical drug
Pharmaceutical compositions, and methods of using the same, are provided utilizing effective amounts of one or more flavones, flavonols, flavanones, isoflavanones and isoflavones to increase cell proliferation in various tissues and cell lines. As examples, the composition and methods of the present invention can be used to increase proliferation of fibroblast cells and, more particularly, in the treatment of wounds as well as strengthening of the skin.
Owner:KIMBERLY-CLARK WORLDWIDE INC
Compositions and methods for regulating lymphocyte activation
InactiveUS20020155604A1Increased proliferationHigh affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsCell activationCell Surface Antigens
The present invention relates to regulation of lymphocyte activation. In particular, it relates to compositions and methods for regulating lymphocyte activation by selectively binding multiple cell surface antigens expressed by the same lymphocyte.
Owner:CYCLACEL PHARMA
Treatment of disease or injury of the nervous system with FTY720
InactiveUS20050090520A1Increased proliferationIncreasing cell proliferationPowder deliveryBiocideProgenitorNervous system
Methods for modulating neurogenesis in vitro and in vivo have been disclosed. The methods comprise contacting neural stem cells with an effective amount of a FTY720 compound. The neurogenesis may involve the modulation of proliferation, differentiation, migration or survival of a non-embryonic neural stem cells or progenitor cells. Also disclosed are methods for the prevention or treatment of neurological disorders comprising administering to a subject a therapeutically effective amount of a FTY720 compound. The disorders that can be treated include various nervous system disorders.
Owner:NEURONOVA AB COMPANY REGISTRATION NO 556703 0118
Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp
InactiveUS20070056058A1Speed upIncreasing cell proliferationBacteriaSugar derivativesMutated proteinPlant cell
Disclosed are mutant CDK inhibitor (CKI) polypeptides having dominant negative antagonist activity against wild-type CKI proteins, as well as related compositions, including nucleic acids and vectors encoding the mutant CKI polypeptides and transformed host cells and transgenic plants comprising such nucleic acids and vectors. Also disclosed are related methods for using the mutant proteins to modulate cell division in cells, particularly plant cells.
Owner:TARGETED GROWTH
Methods for modulating osteochondral development using bioelectrical stimulation
ActiveUS20060293724A1Maximize utilizationMaximize applicationElectrotherapyStress based microorganism growth stimulationCo administrationOsteoblast
Compositions and methods are provided for modulating the growth, development and repair of bone, cartilage or other connective tissue. Devices and stimulus waveforms are provided to differentially modulate the behavior of osteoblasts, chondrocytes and other connective tissue cells to promote proliferation, differentiation, matrix formation or mineralization for in vitro or in vivo applications. Continuous-mode and pulse-burst-mode stimulation of cells with charge-balanced signals may be used. Bone, cartilage and other connective tissue growth is stimulated in part by nitric oxide release through electrical stimulation and may be modulated through co-administration of NO donors and NO synthase inhibitors. Bone, cartilage and other connective tissue growth is stimulated in part by release of BMP-2 and BMP-7 in response to electrical stimulation to promote differentiation of cells. The methods and devices described are useful in promoting repair of bone fractures, cartilage and connective tissue repair as well as for engineering tissue for transplantation.
Owner:MEDRELIEF
Lymphocytes; methods
InactiveUS20050048054A1Reduce cell proliferationIncreasing cell proliferationImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against cell receptors/antigens/surface-determinantsRegulatory T cellLymphocyte
Owner:SCHERING CORP
Use of Rhodiola crenulata extract via the topical route
InactiveUS20050048138A1Slow downImprove plasticityCosmetic preparationsBiocideActive agentDesquamation
The invention relates to the use of a Rhodiola crenulata extract, via the topical route, for increasing the energy metabolism of the cutaneous tissues of a subject. The invention relates notably to topical compositions which comprise an active agent for increasing the energy metabolism of the cutaneous tissues of a subject, said active agent being a Rhodiola crenulata extract. The present invention enables making a cosmetic care such as fighting against, or slowing down or preventing the loosening of the cutaneous tissue, increasing the plasticity of the cutaneous tissue, exerting an anti-wrinkle effect or slowing down or preventing the appearance of wrinkles, fighting against, slowing down or preventing the appearance of acne, exerting a depigmenting effect of the cutaneous tissue, in particular of the skin, and promoting desquamation of the cutaneous tissue (or “peeling”).
Owner:BASF BEAUTY CARE SOLUTIONS FRANCE SAS
Alginate Biomaterials for the Treatment of Hepatic Disorders
ActiveUS20100247652A1Sustaining serum albumin levelLower Level RequirementsPowder deliveryBiocideDiseaseLiver tissue
The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and / or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Compositions of stem cells and stem cell factors and methods for their use and manufacture
Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture.
Owner:STEMEDICA CELL TECH
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
ActiveUS20170199193A1Promote degradationGreat co-stimulatory effectOrganic active ingredientsMicrobiological testing/measurementMedicineBiomarker (petroleum)
A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
Owner:CELGENE CORP
Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
PendingUS20200165569A1Increasing cell proliferationEnhance cell viabilitySkeletal/connective tissue cellsCell culture active agentsYAP1Ingested food
Provided herein are methods to increase the culture density and / or thickness of a cellular biomass in a cultivation infrastructure, to improve the culture of cells in the absence of serum in a cultivation infrastructure, and to promote anchorage-independent growth of a cellular biomass in a cultivation infrastructure. The methods comprise inhibiting the HIPPO signaling pathway, for example, by activating YAP1, activating TAZ, and / or inhibiting MOB1, LATS1 kinase, LATS2 kinase, WW45, MST1 kinase, and / or MST2 kinase in the cellular biomass. In some embodiments, the cellular biomass is harvested from the cultivation infrastructure for the formulation of cell-based food products or ingredients, such as animal meat manufactured from cells in an ex vivo process or for therapeutic applications such as organ or tissue transplantation or grafting.
Owner:UPSIDE FOODS INC
Therapeutic compositions comprising polyhydroxyltate fatty alcohol derivatives and uses thereof
Therapeutic compositions comprising pharmaceutically effective amounts of isolated polyhydroxylated fatty alcohols, in particular suitable for topical or systemic administration. A method for the isolation of a natural polyhydroxylated fatty alcohol from a fruit or vegetable source is also disclosed.
Owner:MERETZKI SHAI +2
Compounds for stimulating stem cell proliferation including spirulina
InactiveUS20080085330A1Increasing stem cell proliferationIncrease measurable indicator of proliferationOrganic active ingredientsBiocideDiseaseDamages tissue
A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these. For example, a supplement comprising wild blueberry, green tea extract, carnosine, vitamin D3, and a Spirulina and / or an AFA-Omega (EtOH) exhibited a synergistic and unexpected association with substantially increased proliferation of bone marrow stem cells and CD34+. A therapeutic amount of a substance that is associated with a substantial increase in stem cells may be used to prevent and repair damages tissues of the brain, due to stroke, the heart, due to coronary artery disease or a heart attack.
Owner:UNIV OF SOUTH FLORIDA
Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
ActiveUS20120184609A1Reduce productionIncreasing cell proliferationBiocideDigestive systemVitamin CEnantiomer
Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
Owner:IC MEDTECH CORP
Compositions and Methods For Treating Bone Formation Disorders
InactiveUS20090263363A1Increasing cell proliferationIncreased cyclin D expression levelBiocidePeptide/protein ingredientsBone formationOsteoporosis
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone formation (e.g., osteoporosis).
Owner:NORTHWESTERN UNIV
Method for modulating gene expression in epithelial cells
InactiveUS20070010547A1Enhancing epithelial cell proliferationIncreasing cell proliferationBiocideCyclic peptide ingredientsRegulator geneCell biology
Owner:GLIAMED
Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient
InactiveUS20090181888A1Increasing cell proliferationBroaden applicationPeptide/protein ingredientsReceptors for hormonesAdditive ingredientSkin Injury
The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient.
Owner:UNIVERSITY OF MIYAZAKI +2
Wnt surrogate molecules and uses thereof
ActiveUS20200308287A1Increase body weightPromoting liver regenerationHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseAgonist
Owner:SURROZEN OPERATING INC
Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing
ActiveUS9962360B2Increasing cell proliferationIncreased proliferationCompound screeningCosmetic preparationsWound healingTrimebutine
The invention relates to compositions and methods useful for enhancing hair growth and promoting skin regeneration. Particularly, the invention provides topical compositions including trimebutine, salts, or active metabolites thereof, for enhancing or inducing hair growth and promoting skin regeneration. Compositions comprising trimebutine or a pharmaceutically acceptable salt or active metabolite thereof and their use in the method of promoting hair growth or skin regeneration. Preferably trimebutine is trimebutine maleate or N-desmethyl trimebutine. Compositions are preferably in a form for topical administration, such as a gel.
Owner:HOSPITAL FOR SICK CHILDREN
Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
InactiveUS20140286910A1Increase speedHigh yieldBiocideNervous system cellsOxygen tensionStem cell culture
Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture. The invention also contemplates the use of such stem cells in the treatment of neurodegenerative disorders including Alzheimer's disease and stroke.
Owner:STEMEDICA INT +1
Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences
InactiveUS7074398B1Increasing cell proliferationBiocideGenetic material ingredientsDiseaseInducible promoters
The present invention relates to retroviral vectors carrying DNA sequences encoding SDI-1, function analogues of SDI-1, or fragments thereof, or antisense SDI-1 DNA sequences, and especially retroviral vectors carrying the SDI-1 or antisense SDI-1 sequences under the transcriptional control of target cell specific regulatory elements or promoters or X-ray inducible promoters. Further, the invention relates to the use of such retroviral vectors for the production of recombinant retroviral particles useful for the treatment of disorders or diseases responsive to the anti-proliferative activity of SDI-1, or the proliferative activity of antisense SDI-1 sequences.
Owner:GUENZBURG WALTER H +2
Kinase inhibitor compounds and compositions and methods of use
PendingUS20220064146A1Inhibiting kinase activityInhibitory activityNervous disorderOrganic chemistryPancreatic A CellsPancreatic hormone
Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, N—Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
Owner:MT SINAI SCHOOL OF MEDICINE
Antibodies specific to human nectin-2
PendingUS20220112283A1Increased proliferationIncreasing cell proliferationMammal material medical ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsGlycoproteinTransmembrane glycoprotein
The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.
Owner:YISSUM RES DEV CO OF THE HEBREW UNIV OF JERUSALEM LTD +1
Polymeric films to enhance cell growth
InactiveUS20100080987A1Increasing cell proliferationImproved cell proliferation characteristicLayered productsRecord information storagePolymer thin filmsPolymer coatings
The present invention provides a method for creating surface-tailored polymer coating for improved cells proliferation by converting one or more carbonaceous monomers each comprising one or more functional groups to a monomer vapor; contacting the monomer vapor and a substrate; and igniting a radio frequency plasma glow discharge to polymerize the monomer vapor to form surface-tailored polymer coating on the substrate at a thicknesses of between 25 and 300 nm and has a functional group surface density of between 3 and 9%, wherein the surface-tailored polymer coating enhances cell proliferation.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Composition and method for corneal proliferation
InactiveUS20150051558A1Increasing cell proliferationRapid and substantial and cornea re-growthBiocideSenses disorderProgenitor cellCornea
Disclosed herein in exemplary embodiments are methods and compositions for repairing or treating a defected cornea in a patient in need. The methods and compositions including, for example, administering a dose of a composition to the patient, wherein the composition comprises may be administered to an intraocular area of the patient via a container having a spout for ophthalmic delivery. The methods and compositions promote progenitor cell migration and increase cellular proliferation in the cornea of the patient.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Collagen-mimetic peptide mediated delivery of nucleic acid carriers for efficient delivery from collagen
PendingUS20200179490A1Increase productionPromote migrationConnective tissue peptidesPeptide/protein ingredientsCell-Extracellular MatrixECM Protein
The present invention provides a composition for delivering a polynucleotide into cells via a polyplex. The polyplex comprises the polynucleotide and a polymer. The composition comprises the polyplex, a collagen-mimetic peptide (CMP) and collagen fragments. The CMP is bound to the polyplex and the collagen fragments. Also provided are the uses of the composition in methods of delivering a polynucleotide into cells as well as methods of improving wound healing in a subject, enhancing cell proliferation in a subject, enhancing production of extracellular matrix by cells in a subject and / or enhancing cell migration by cells in a subject.
Owner:UNIVERSITY OF DELAWARE
Methods for detecting cancer cells by using nucleic acid encoding for IGF-1 receptor interacting proteins
InactiveUS7348165B2Increasing cell proliferationModulate signal transduction of IGF-Sugar derivativesMicrobiological testing/measurementWilms' tumorMolecular biology
The invention relates generally to a method for the detection of the proliferation of a tumor cell and more specifically wherein said method comprises nucleic acids (SEQ ID NO:1) encoding IIP-1.
Owner:F HOFFMANN LA ROCHE & CO AG
Lung injury repair compositions and methods
ActiveUS20160120934A1Increasing cell proliferationInduced proliferationRespiratory disorderEnzyme inhibitor ingredientsProgenitorIsrapafant
The present invention provides a pharmaceutical composition comprising Protein Kinase C Zeta (PKC-ζ) inhibitor and therapeutic methods for preventing or treating a pathological condition or symptom or for inducing proliferation of lung progenitor cells in a mammal by administering the PKC-ζ inhibitor.
Owner:UNIV OF IOWA RES FOUND
Method for enhancing epithelial cell proliferation and uses thereof
InactiveUS20070010546A1Enhancing epithelial cell proliferationIncreasing cell proliferationBiocideCyclic peptide ingredientsRectal epitheliumPathology
The present invention is directed to uses of GM-284 for enhancing epithelial cell proliferation. The present invention is also provides methods for treating a keratinocyte-associated disorder in a subject in need of treatment.
Owner:GLIAMED
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com